John P. Kenny - Jun 24, 2022 Form 4 Insider Report for MERIDIAN BIOSCIENCE INC (VIVO)

Role
Chief Executive Officer, Director
Signature
/s/ Jeffery T. Pinkston as Attorney-in-fact for John P. Kenny
Stock symbol
VIVO
Transactions as of
Jun 24, 2022
Transactions value $
-$1,516,165
Form type
4
Date filed
6/28/2022, 09:42 AM
Previous filing
Jun 24, 2022
Next filing
Oct 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIVO Common Stock Options Exercise $137K +13.6K +5.11% $10.10 279K Jun 24, 2022 Direct
transaction VIVO Common Stock Sale -$407K -13.6K -4.87% $30.00 265K Jun 24, 2022 Direct F1, F2
transaction VIVO Common Stock Options Exercise $621K +61.4K +23.17% $10.10 327K Jun 27, 2022 Direct
transaction VIVO Common Stock Sale -$1.87M -61.4K -18.81% $30.39 265K Jun 27, 2022 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIVO Stock Options (Right to Buy) Options Exercise $0 -13.6K -9.61% $0.00 127K Jun 24, 2022 Common Stock 13.6K $10.10 Direct F5, F6
transaction VIVO Stock Options (Right to Buy) Options Exercise $0 -61.4K -48.19% $0.00 66K Jun 27, 2022 Common Stock 61.4K $10.10 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
F2 The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.11. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
F3 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
F4 The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.76. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
F5 The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
F6 These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date.
F7 The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.